Urethral Surveillance after Radical Cystectomy A 10-year Regional Experience
Main Article Content
Radical cystectomy (RC) is commonly performed with curative intent for primary or recurrent high-risk non-muscle-invasive and muscle-invasive bladder cancers. Urethral recurrence (UR) within the residual urethra, often proximally where the epithelial lining comprises urothelial cells, is a rare but well-described occurrence associated with adverse clinical outcomes. Current national guidelines therefore suggest that male patients with a defunctioned urethra should undergo annual endoscopic or urethral washing surveillance for 5 years following RC, to identify UR early, where local disease management (e.g., urethrectomy) may still be possible. Anecdotally, however, urethroscopy and urethral washing cytology appear to be infrequently performed. Our regional trainee-led research collaborative evaluated the frequency and tim-ing of urethral surveillance in the West Midlands in comparison to National Institute for Health and Care Excellence (NICE) guidelines.
Patients and methods
Our 10-year cross-sectional retrospective regional analysis included 495 patients from 2008–2018. Clinical and demographic data were collected alongside cross-sectional staging and imaging, and timings and frequency of urethral endoscopic surveillance or urethral washing cytology.
Overall, 159 (35.2%) patients received one (or more) surveillance urethroscopy. A minority of surveillance urethroscopies were annual, with hugely variable frequency or intervals ranging from every 4–50 months. Only 81 (19.6%) patients had urethral surveillance in keeping with the frequency suggested by NICE guidelines. At 10 years, disease-specific mortality was 42.0%, and overall or all-cause mortality was 44.7%. The overall UR rate (as detected by staging CT and/or urethroscopy) was 1.0% (n = 4); all four cases of UR were found in patients with positive urethral margins after RC who did not undergo immediate urethrectomy.
Our regional urethral surveillance practice following RC is heterogeneous and suboptimal in comparison to NICE guidelines. Our UR rate was so low that we are unable to assert whether early detection has any clinical benefit, and therefore we cannot advocate routine urethral surveillance, but suggest that patients with positive urethral margins should be offered immediate urethrectomy post RC. In addition, we encourage collaborative urological research and data collection to generate higher volume series, more representative and generalisable data, and more meaningful conclusions.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.
2. Sherwood JB, Sagalowsky AI. The diagnosis and treatment of urethral recurrence after radical cys-tectomy. Urol Oncol. 2006;24(4):356–61. https://doi.org/10.1016/j.urolonc.2005.11.027
3. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004;172(4):1342–7. https://doi.org/10.1097/01.ju.0000138208.07426.19
4. Huguet J, Monllau V, Sabate S, Rodriguez-Faba O, Algaba F, Palou J, et al. Diagnosis, risk factors, and outcome of urethral recurrences following radical cystectomy for bladder cancer in 729 male patients. Eur Urol. 2008;53:785–93. https://doi.org/10.1016/j.eururo.2007.06.045
5. EAU Guidelines. Muscle-invasive and met-astatic bladder cancer. Edn. presented at the EAU Annual Congress Amsterdam 2022. The Netherlands: EAU Guidelines Office, Arnhem. ISBN 978-94-92671-16-5
6. Bladder cancer: Diagnosis and management. NICE guideline [NG2]: 25 February 2015. [cited 2022 Februray 02]. Available from: https://www.nice.org.uk/guidance/ng2
7. Soukup V, Babjuk M, Bellmunt J, Dalbagni G, Giannarini G, Hakenberg OW, et al. Follow-up after surgical treatment of bladder cancer: A critical analysis of the literature. Eur Urol. 2012;62(2):290– 302. https://doi.org/10.1016/j.eururo.2012.05.008
8. Cagiannos I, Morash C. Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J. 2009;3(6 Suppl4):S237–42. https://doi.org/10.5489/cuaj.1205
9. Laukhtina E, Mori K, Andrea DD, Moschini M, Abufaraj M, Soria F, et al. Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urol Oncol. 2021;39(12):806–15. https://doi.org/10.1016/j.urolonc.2021.06.009
10. Social Science Statistics online software [Internet]. [cited 2021 Mar 19]. Available from: https://www.socscistatistics.com
11. Perlis N, Turker P, Bostrom PJ, Kuk C, Mirtti T, Kulkarni G, et al. Upper urinary tract and urethral recurrences following radical cystectomy: Review of risk factors and outcomes between centres with different follow-up protocols. World J Urol. 2013;31(1): 161–7. https://doi.org/10.1007/s00345-012-0905-2
12. Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol. 2017; 14(4):221–34. doi: 10.1038/nrclinonc.2016.188
13. Pones M, D’Andrea D, Mori K, Abufraj M, Moschini M, Comperat E, et al. Differential prognosis and response of denovo vs. secondary muscle-invasive bladder cancer: An updated systematic review and meta-analysis. Cancers (Basel). 2021;13(10):2496. https://doi.org/10.3390/cancers13102496
14. Li X, Wang W, Zhu G, He W, Gou X. Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer: A meta-analysis of 9498 patients. Oncotarget. 2018;9(2):2782–96. https://doi.org/10.18632/oncotarget.23451